Latest Breaking News On - அமெரிக்கன் சமூகம் ஆஃப் புற்றுநோயியல் - Page 1 : comparemela.com

Immunocore Holdings Limited: Immunocore Reports First Quarter 2021 Financial Results Launched includes $287 million in net proceeds from initial public offering and concurrent private placement in February 2021 Holdings Plc (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and autoimmune disease, today announced its results for the quarter ended March 31, 2021. Highlights for the quarter included the presentation of the Phase 3 randomized data from the Company s lead candidate tebentafusp in the plenary clinical trial session at the American Association for Cancer Research (AACR) Annual Meeting, the launch of a global early access program for tebentafusp, and the successful completion of the Company s initial public offering resulting in net proceeds of $287 million.

United statesBahija jallalDebra nielsenClayton robertsonRoys herbstExchange commission onMeeting libraryMelinda gates foundationCompany annual report on formTranslational research at yale cancer centerHead of communicationsAmerican society of oncologyCompany phaseCompany board of directorsDrug administrationCancer center